Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
Cheng A, Harris S, Giorgino F, Seufert J, Ritzel R, Khunti K, Lauand F, Melas-Melt L, Westerbacka J, Bosnyak Z, Rosenstock J. Cheng A, et al. Among authors: bosnyak z. Diabetes Obes Metab. 2020 Mar;22(3):346-354. doi: 10.1111/dom.13901. Epub 2019 Dec 20. Diabetes Obes Metab. 2020. PMID: 31646724 Free PMC article. Clinical Trial.
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frías JP, Roussel R, Bolli GB. Rosenstock J, et al. Among authors: bosnyak z. Diabetes Care. 2018 Oct;41(10):2147-2154. doi: 10.2337/dc18-0559. Epub 2018 Aug 13. Diabetes Care. 2018. PMID: 30104294 Clinical Trial.
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
Sullivan SD, Nicholls CJ, Gupta RA, Menon AA, Wu J, Westerbacka J, Bosnyak Z, Frias JP, Bailey TS. Sullivan SD, et al. Among authors: bosnyak z. Diabetes Obes Metab. 2019 Sep;21(9):2123-2132. doi: 10.1111/dom.13793. Epub 2019 Jun 21. Diabetes Obes Metab. 2019. PMID: 31144445 Free PMC article.
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
Haluzík M, Cheng A, Müller-Wieland D, Westerbacka J, Bosnyak Z, Lauand F, Melas-Melt L, Karalliedde J, Rosenstock J, Bolli GB. Haluzík M, et al. Among authors: bosnyak z. Diabetes Obes Metab. 2020 Aug;22(8):1369-1377. doi: 10.1111/dom.14043. Epub 2020 Apr 28. Diabetes Obes Metab. 2020. PMID: 32243043 Free PMC article. Clinical Trial.
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
Bolli GB, Landgraf W, Bosnyak Z, Melas-Melt L, Home PD. Bolli GB, et al. Among authors: bosnyak z. Diabetes Obes Metab. 2020 Sep;22(9):1664-1669. doi: 10.1111/dom.14065. Epub 2020 May 29. Diabetes Obes Metab. 2020. PMID: 32314521 Free PMC article.
The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM.
Renard E, Ikegami H, Daher Vianna AG, Pozzilli P, Brette S, Bosnyak Z, Lauand F, Peters A, Pilorget V, Jurišić-Eržen D, Kesavadev J, Seufert J, Wilmot EG. Renard E, et al. Among authors: bosnyak z. Diabetes Metab Res Rev. 2021 Oct;37(7):e3430. doi: 10.1002/dmrr.3430. Epub 2021 Mar 2. Diabetes Metab Res Rev. 2021. PMID: 33369842 Free PMC article.
Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study.
Wilmot EG, Close KL, Jurišić-Eržen D, Bruttomesso D, Ampudia-Blasco FJ, Bosnyak Z, Roborel de Climens A, Bigot G, Peters AL, Renard E, Berard L, Calliari LE, Seufert J. Wilmot EG, et al. Among authors: bosnyak z. Diabetes Obes Metab. 2021 Aug;23(8):1892-1901. doi: 10.1111/dom.14416. Epub 2021 Jun 14. Diabetes Obes Metab. 2021. PMID: 33914401
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sullivan SD, Bailey TS, Roussel R, Zhou FL, Bosnyak Z, Preblick R, Westerbacka J, Gupta RA, Blonde L. Sullivan SD, et al. Among authors: bosnyak z. Diabetes Obes Metab. 2018 Sep;20(9):2148-2158. doi: 10.1111/dom.13345. Epub 2018 Jun 25. Diabetes Obes Metab. 2018. PMID: 29938887 Free PMC article.
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyên-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Freemantle N, et al. Among authors: bosnyak z. Curr Med Res Opin. 2020 Apr;36(4):571-581. doi: 10.1080/03007995.2019.1708287. Epub 2020 Jan 19. Curr Med Res Opin. 2020. PMID: 31865758 Free article. Clinical Trial.
30 results